Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa
about
Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.Thyroid dysfunctions secondary to cancer immunotherapy.
P2860
Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Serologic evidence of autoimmu ...... with adjuvant interferon alfa
@ast
Serologic evidence of autoimmu ...... with adjuvant interferon alfa
@en
type
label
Serologic evidence of autoimmu ...... with adjuvant interferon alfa
@ast
Serologic evidence of autoimmu ...... with adjuvant interferon alfa
@en
prefLabel
Serologic evidence of autoimmu ...... with adjuvant interferon alfa
@ast
Serologic evidence of autoimmu ...... with adjuvant interferon alfa
@en
P2093
P2860
P1433
P1476
Serologic evidence of autoimmu ...... with adjuvant interferon alfa
@en
P2093
Ahmad A Tarhini
Cindy A Sander
Donghoon Shin
John M Kirkwood
Joseph Stuckert
Sandra J Lee
P2860
P304
P356
10.1097/CMR.0000000000000050
P407
P577
2014-04-01T00:00:00Z